I sure hope that you are right. But I am having trouble with your timing. If the data is due "by the end of the year", and then we speak with the FDA, where does the two weeks come in? Perhaps you were speaking about the data itself and not the actual decision. If so, how long do you think that the discussion and the subsequent decision will take? Outright approval while a bit of a dream scenario, could actually happen. Then the company would have to hustle to find someone to partner with for expense assistance and selling expertise.
The FDA when all data is in takes about 1 week to review. 1 week max. Now in a case like DNDN 2% effective. they drag their feet. WSJ had to apply pressure. On the other end of the spectrum is NKTR 102. 1 week. The best part about NKTR is the safety profile and 3wk dosing. All the way around nktr 102 is on center.